跳转至内容
Merck
CN

SML3369

A-674563 hydrochloride

≥98% (HPLC)

别名:

αS-[[[5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]-benzeneethanamine hydrochloride, (1S)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine hydrochloride, (2S)-1-(5-(3-methyl-1H-indazol-5-yl)pyridin-3-yloxy)-3-phenylpropan-2-amine hydrochloride, A 674563 hydrochloride, A674563 hydrochloride

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C22H22N4O · xHCl
分子量:
358.44 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

[nH]1nc(c2c1ccc(c2)c3cncc(c3)OC[C@@H](N)Cc4ccccc4)C

InChI key

BPNUQXPIQBZCMR-IBGZPJMESA-N

Biochem/physiol Actions

A-674563 is an orally available ATP-competitive pan-AKT (PKB, protein Kinase B) inhibitor (AKT1 Ki = 11 nM) with additional potency against PKA, Cdk2 GSK3β (IC50 = 1.4, 4.2,10 nM, respectively). A-674563 reduces the phosphorylation of cellular Akt substrates (0.1-10 μM; MiaPaCa-2) and enhances paclitaxel efficacy in a PC-3 xenograft model in mice in vivo (40 mg A-674563/kg via p.o. b.i.d. for 21 days, 15 mg paclitaxel/day on days 20, 24, 28).
Orally available ATP-competitive pan-AKT (PKB, protein Kinase B) inhibitor that enhances paclitaxel efficacy in a PC-3 xenograft model in mice in vivo.


存储类别

11 - Combustible Solids

wgk

WGK 3



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



全球贸易项目编号

货号GTIN
SML3369-10MG04065268435243
SML3369-50MG04065268435250